1.
The Abu Dhabi Investment Authority (ADIA) to
acquire about 3% in Intas Pharmaceuticals for US$250-270 million at a valuation
of US$8.5 Billion.
2.
Biocon Biologics wins US$90 Million contract
from Malaysia to supply human insulin.
3.
Suven Pharmaceuticals is acquiring Casper
Pharma for US$20.2 Million.
4.
Lupin, Yabao announce strategic partnership
in China for paediatric formulations.
5.
Intas Pharma partners with Comera Life
Sciences for bio-innovative biologic medicines.
6.
Marksans Pharma to acquire 100% stake in
Dubai-based Access Healthcare for Medical Products L.L.C.
7.
Bharat Biotech expands Covaxin pact with
Ocugen to entire North America, seeks EUA for 2-18-year-olds in Mexico.
8.
Intas Pharmaceuticals has signed an exclusive
license and supply agreement with Axantia Holding, a leading pharmaceutical
company in the Middle East for Ranibizumab.
9.
Lupin has entered into a
licensing agreement with Alvion Pharmaceuticals to commercialise medicines for
cardiometabolic diseases in the Southeast Asia region.
10. Bioventus picks up partner CartiHeal in acquisition
deal worth up to US$450 Million.
11. Regeneron sees skin cancer potential beyond PD-1s with
US$250 Million Checkmate acquisition.
12. Asahi Kasei Medical to acquire US-based Bionova
Scientific.
13. Shionogi and NEC collaborate on hep B vaccine
development.
14. Elekta and GE Healthcare have signed a global commercial collaboration agreement in the field of radiation oncology.
Highlights at Aagami:
1. Aagami already has 15 face to face meetings setup already for BIO International Convention 2022 (June 13-16, San Diego). Time options filling up fast. If you would like to meet, kindly send us your meeting request at the earliest, please.
INFOCUS: Select opportunities available:
For Acquisition:
1. Mountain View Pharma (MVP) including its PharmaPEG® technology,
product candidates, data package of ~20 drug candidates, IP etc.- for
Next-generation biologics and substantial returns. Available at a very
reasonable price.
For Partnering/Licensing/ Investment:
1. Investment in the US FDA approved portable MRI Guided Treatment, Diagnosis and Screening ($40 Million Series C Open). For Urology applications.
2. Licensing/Strategic Partnership: Next-gen AI powered imaging to pinpoint the IVF +/- 12 hour window of opportunity to implant the embryo. First solution that supports the science of uterine receptivity vs. a physician's estimates or inaccurate ultrasound. Market Launch early 2024.
3. Series B Open- Novel Evolution of Portable MRI and Robotics for Strokes and TBI.
4. Midwest US based Pharma’s First-in-Class Non-Opioid Analgesic for both chronic and acute Pain Relief – Seeking funding/licensing/co-development partnerships.
5. Licensing, Co-development - 505(b)(2) low cost near market IP protected Bendamustine. Can be brought to market in 2024 without any infringement. Negligible competition (3) at the moment. Good market share potential.
6. Available for licensing: Phase I asset for Moderate-Severe Pain; Fast Track designation; Clinical Study on-going.
7. Available for licensing: Transdermal smart patch asset with Proprietary technology for Alzheimer’s Disease; IND filing in progress. Safer and non-irritable.
8.Technology Licensing: Easy to apply Microneedle Array Patch (MAP) system to deliver drugs, vaccines; better immune response than injection. A painless and efficient replacement to Syringes.